Is DraftKings Winning the Customer Acquisition War in Sports Betting?
How DraftKings Stacks Up Against FanDuel and BetMGM
In the race for sports betting dominance, FanDuel and BetMGM remain DraftKings' closest competitors, but recent trends show it pulling ahead on multiple fronts.FanDuel, owned by Flutter Entertainment plc FLUT, continues to lead in market share but is starting to face pressure. DraftKings' surging live betting handle and product enhancements are narrowing the gap, especially in states where FanDuel once held a clear lead. Unlike FanDuel's heavier reliance on aggressive promotions, DraftKings is proving more efficient in customer acquisition and retention.Meanwhile, BetMGM, backed by MGM Resorts International MGM and Entain, has struggled to match DraftKings' pace in product innovation. Though BetMGM boasts strong iGaming performance, it lags in sportsbook engagement. DraftKings' seamless integration of acquired tech and rapid adoption of features like same-game parlays and live micro-bets gives it a distinct edge.
DKNG's Price Performance, Valuation & Estimates
Shares of DKNG have gained 30.3% in the past three months compared with the industry's growth of 31.2%.
Price Performance
Image Source: Zacks Investment Research
DraftKings is currently trading at a premium compared with the industry peers, with a forward 12-month price-to-sales ratio of 5.69X.
P/S (F12M)
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DKNG's 2025 and 2026 earnings implies a year-over-year uptick of 226.7% and 61.3%, respectively.
Image Source: Zacks Investment Research
DKNG currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MGM Resorts International (MGM) : Free Stock Analysis Report
DraftKings Inc. (DKNG) : Free Stock Analysis Report
Flutter Entertainment PLC (FLUT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Cardinal Health expands urology focus with $1.9bn Solaris Health deal
US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio
Yahoo
16 minutes ago
- Yahoo
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
NBA's 80th season tips off with Rockets at Thunder on October 21
Reigning NBA champion Oklahoma City will play host to the Houston Rockets on October 21 to tip off the league's 80th season, NBA officials announced on Tuesday. The Thunder will raise their championship banner before reigning NBA Most Valuable Player Shai Gilgeous-Alexander and his teammates face the Kevin Durant-led Rockets. The game will be the first of two on opening night for the 2025-26 season with the later start featuring the Golden State Warriors at the Los Angeles Lakers, as Golden State star guard Stephen Curry and Lakers' playmaker LeBron James -- both four-time NBA champions -- meet for the 57th time in their iconic careers. James, a 40-year-old forward, will become the first player in NBA history to compete in a 23rd NBA campaign while teammate Luka Doncic plays in his first season opener as a Laker. Durant, a two-time NBA champion and 2014 NBA MVP, was traded from Phoenix to Houston last month as part of an NBA record seven-team deal. The league also confirmed some other contest dates, including its Christmas schedule, ahead of Thursday's release of the full NBA schedule for the 2025-26 campaign. The December 25 lineup includes five NBA games, starting with Cleveland at New York, the Knicks having made a record 57 Christmas appearances. San Antonio will visit Oklahoma City in the Thunder's first game on December 25 since 2018 followed by Dallas at Golden State with ex-Warrior Klay Thompson returning to San Francisco with the Mavericks, then Houston at the Lakers and Minnesota at Denver. On the second night of the season on October 22, the Cleveland Cavaliers will visit New York while the San Antonio Spurs open their season at Dallas in the NBA debuts for top NBA Draft pick Cooper Flagg of Dallas and second choice Dylan Harper of the Spurs, who also welcome back French star Victor Wembanyama after he missed the end of last season with deep vein thrombosis in his shoulder. The following night sees Oklahoma City at Indiana in a rematch of last season's NBA Finals followed by Denver at Golden State with three-time NBA MVP Nikola Jokic of the Nuggets facing two-time NBA MVP Curry. October 27 will see Cleveland at Detroit and Denver at Minnesota. Martin Luther King Jr. Day games on January 19 will include Milwaukee at Atlanta, Oklahoma City at Cleveland, Dallas at New York and Boston at Detroit. js/ea